Subsequent Malignant Neoplasms in Childhood Cancer Survivors: Identifying Risks and Screening Recommendations. Hematol Oncol Clin North Am 2026 Jun;40(3):403-415
Date
06/11/2026Pubmed ID
42270201DOI
10.1016/j.hoc.2026.02.002Scopus ID
2-s2.0-105041600055 (requires institutional sign-in at Scopus site)Abstract
A subsequent malignant neoplasm (SMN) is defined as a distinctly new histologic malignant neoplasm that occurs after completion of treatment of a primary malignancy or hematopoietic stem cell transplant. The risk for SMNs in survivors is estimated to be between 2% and 20%. Many risk factors associated with the development of SMNs including radiation, chemotherapy, underlying genetic diagnoses, and lifestyle factors, which all must be understood to provide appropriate SMN screening recommendations for survivors. Many different screening guidelines exist-choosing the appropriate set for each patient requires an understanding of all factors that impact individualized SMN risk.
Author List
Becktell K, Cotchett K, Volmy R, Phelan RAuthors
Kerri Becktell MD Associate Professor in the Pediatrics department at Medical College of WisconsinRachel A. Phelan MD, MPH Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Cancer SurvivorsChild
Early Detection of Cancer
Humans
Neoplasms
Neoplasms, Second Primary
Risk Factors









